Geron Corporation (GERN) vs Lexicon Pharmaceuticals, Inc. (LXRX)
A side-by-side comparison of Geron Corporation and Lexicon Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GERN
Geron Corporation
$1.23HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
LXRX
Lexicon Pharmaceuticals, Inc.
$1.78HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Total return — GERN vs LXRX
growth of $100 · dividends reinvested · last 10yGERN -46.7% (-6.1%/yr)LXRX -90.8% (-21.2%/yr)GERN compounded faster over this window
Log scale — wide-divergence pair
GERN LXRX
GERN vs LXRX: by the numbers
- •GERN is the larger company ($790M vs $788M market cap).
- •Both run net losses; GERN's is the smaller (-34.17% vs -147.38% net margin).
- •GERN grew revenue faster over the past five years (247.85% vs 42.36% CAGR).
Metrics side by side
Valuation
| Metric | GERN | LXRX |
|---|---|---|
| P/S ratio | 3.86 | 19.01 |
| P/B ratio | 3.61 | 4.52 |
Profitability
| Metric | GERN | LXRX |
|---|---|---|
| Gross margin | 97.42% | 98.85% |
| Operating margin | -29.28% | -98.21% |
| Net margin | -34.17% | -147.38% |
| ROE | -31.97% | -35.02% |
| ROIC | -8.34% | -23.16% |
Growth (annualized)
| Metric | GERN | LXRX |
|---|---|---|
| Revenue CAGR (5Y) | 247.85% | 42.36% |
| Total return CAGR (5Y) | -1.87% | -18.54% |
Frequently asked
- Which has grown faster, GERN or LXRX?
- Over the past five years, GERN grew revenue faster — GERN at a 247.85% CAGR versus LXRX at 42.36%.
- How have GERN and LXRX total returns compared?
- Over the past 10 years, GERN delivered -6.18% and LXRX delivered -21.03% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Geron ROELexicon Pharmaceuticals ROEGeron operating marginLexicon Pharmaceuticals operating marginGeron revenue growthLexicon Pharmaceuticals revenue growthGeron free cash flowLexicon Pharmaceuticals free cash flow
Geron & Lexicon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.